Clinical Trials Browser

Glioblastoma × pembrolizumab × 90 days × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06556563 2026-05-01

EF-41

Phase 3 Recruiting

741 enrolled

CNS

Glioblastoma

NCT02287428 2026-04-17

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Phase 1 Active not recruiting

56 enrolled

CNS

Glioblastoma

NCT03277638 2026-04-09

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

Phase 1/2 Active not recruiting

32 enrolled

CNS

Brain Neoplasms, Glioblastoma

NCT07301268 2026-04-08

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Phase 2 Recruiting

36 enrolled

CNSSarcoma

Astrocytoma, Glioblastoma, Gliosarcoma

NCT03197506 2026-03-25

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

Phase 2 Active not recruiting

52 enrolled 19 charts

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT05463848 2026-03-04

Surgical Pembro +/- Olaparib w TMZ for rGBM

Phase 2 Recruiting

78 enrolled

CNS

Glioblastoma

Clinical Trials

LEAP-005

EF-41

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

Surgical Pembro +/- Olaparib w TMZ for rGBM